These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 33202418)

  • 1. Hematoxylin binds to mutant calreticulin and disrupts its abnormal interaction with thrombopoietin receptor.
    Jia R; Balligand T; Atamanyuk V; Nivarthi H; Xu E; Kutzner L; Weinzierl J; Nedelec A; Kubicek S; Lesyk R; Zagrijtschuk O; Constantinescu SN; Kralovics R
    Blood; 2021 Apr; 137(14):1920-1931. PubMed ID: 33202418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN.
    Elf S; Abdelfattah NS; Baral AJ; Beeson D; Rivera JF; Ko A; Florescu N; Birrane G; Chen E; Mullally A
    Blood; 2018 Feb; 131(7):782-786. PubMed ID: 29288169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.
    Elf S; Abdelfattah NS; Chen E; Perales-Patón J; Rosen EA; Ko A; Peisker F; Florescu N; Giannini S; Wolach O; Morgan EA; Tothova Z; Losman JA; Schneider RK; Al-Shahrour F; Mullally A
    Cancer Discov; 2016 Apr; 6(4):368-81. PubMed ID: 26951227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms.
    Araki M; Yang Y; Masubuchi N; Hironaka Y; Takei H; Morishita S; Mizukami Y; Kan S; Shirane S; Edahiro Y; Sunami Y; Ohsaka A; Komatsu N
    Blood; 2016 Mar; 127(10):1307-16. PubMed ID: 26817954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel molecular mechanism of cellular transformation by a mutant molecular chaperone in myeloproliferative neoplasms.
    Araki M; Komatsu N
    Cancer Sci; 2017 Oct; 108(10):1907-1912. PubMed ID: 28741795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants.
    Chachoua I; Pecquet C; El-Khoury M; Nivarthi H; Albu RI; Marty C; Gryshkova V; Defour JP; Vertenoeil G; Ngo A; Koay A; Raslova H; Courtoy PJ; Choong ML; Plo I; Vainchenker W; Kralovics R; Constantinescu SN
    Blood; 2016 Mar; 127(10):1325-35. PubMed ID: 26668133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homomultimerization of mutant calreticulin is a prerequisite for MPL binding and activation.
    Araki M; Yang Y; Imai M; Mizukami Y; Kihara Y; Sunami Y; Masubuchi N; Edahiro Y; Hironaka Y; Osaga S; Ohsaka A; Komatsu N
    Leukemia; 2019 Jan; 33(1):122-131. PubMed ID: 29946189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Development of myeloproliferative neoplasms by mutant calreticulin: underlying mechanisms].
    Araki M
    Rinsho Ketsueki; 2018; 59(8):1072-1077. PubMed ID: 30185708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MPL overexpression induces a high level of mutant-CALR/MPL complex: a novel mechanism of ruxolitinib resistance in myeloproliferative neoplasms with CALR mutations.
    Yasuda S; Aoyama S; Yoshimoto R; Li H; Watanabe D; Akiyama H; Yamamoto K; Fujiwara T; Najima Y; Doki N; Sakaida E; Edahiro Y; Imai M; Araki M; Komatsu N; Miura O; Kawamata N
    Int J Hematol; 2021 Oct; 114(4):424-440. PubMed ID: 34165774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion.
    Han L; Schubert C; Köhler J; Schemionek M; Isfort S; Brümmendorf TH; Koschmieder S; Chatain N
    J Hematol Oncol; 2016 May; 9(1):45. PubMed ID: 27177927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism underlying the development of myeloproliferative neoplasms through mutant calreticulin.
    Edahiro Y; Araki M; Komatsu N
    Cancer Sci; 2020 Aug; 111(8):2682-2688. PubMed ID: 32462673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rare type 1-like and type 2-like calreticulin mutants induce similar myeloproliferative neoplasms as prevalent type 1 and 2 mutants in mice.
    Toppaldoddi KR; da Costa Cacemiro M; Bluteau O; Panneau-Schmaltz B; Pioch A; Muller D; Villeval JL; Raslova H; Constantinescu SN; Plo I; Vainchenker W; Marty C
    Oncogene; 2019 Mar; 38(10):1651-1660. PubMed ID: 30846848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the CALR interactome in myeloproliferative neoplasms.
    Pronier E; Cifani P; Merlinsky TR; Berman KB; Somasundara AVH; Rampal RK; LaCava J; Wei KE; Pastore F; Maag JL; Park J; Koche R; Kentsis A; Levine RL
    JCI Insight; 2018 Nov; 3(22):. PubMed ID: 30429377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms.
    Ojeda MJ; Bragós IM; Calvo KL; Williams GM; Carbonell MM; Pratti AF
    Hematology; 2018 May; 23(4):208-211. PubMed ID: 28990497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutant calreticulin interacts with MPL in the secretion pathway for activation on the cell surface.
    Masubuchi N; Araki M; Yang Y; Hayashi E; Imai M; Edahiro Y; Hironaka Y; Mizukami Y; Kihara Y; Takei H; Nudejima M; Koike M; Ohsaka A; Komatsu N
    Leukemia; 2020 Feb; 34(2):499-509. PubMed ID: 31462733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upregulation of endogenous thrombopoietin receptor (MPL) with in vivo passage of calreticulin (CALR) mutant Ba/F3 cells, highlighting MPL as the requisite cytokine receptor for CALR mediated transformation.
    Brooks SA; Kim DM; Morse SJ; Nguyen QH; Craver BM; Lai HY; Fleischman AG
    Leuk Res; 2019 Jul; 82():11-14. PubMed ID: 31128484
    [No Abstract]   [Full Text] [Related]  

  • 17. Mutant calreticulin in myeloproliferative neoplasms.
    How J; Hobbs GS; Mullally A
    Blood; 2019 Dec; 134(25):2242-2248. PubMed ID: 31562135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of calreticulin mutations in myeloproliferative neoplasms.
    Araki M; Komatsu N
    Int J Hematol; 2020 Feb; 111(2):200-205. PubMed ID: 31848992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody targeting of mutant calreticulin in myeloproliferative neoplasms.
    Kramer F; Mullally A
    J Cell Mol Med; 2024 Mar; 28(5):e17896. PubMed ID: 37551061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatic mutations of calreticulin in myeloproliferative neoplasms.
    Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
    N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.